The study is conducted in the affiliated hospital of Qinghai University .Patients in the
department of Critical Care Medicine and Emergency Intensive Care Unit will be eligible for
inclusion if they meet the Berlin criteria.Two researchers assess pulmonary artery pressure
and right heart function of patients who are enrolled.
To investigate if the inflammatory protein, high mobility group box 1 (HMGB1), along with
other inflammatory mediators, is elevated in pediatric patients with congenital heart disease
(CHD) and pulmonary hypertension as compared to those with CHD alone, or with healthy
The aim of this study is to investigate the underlying inflammatory profile in patients with
chronic lung disease and determine the association pulmonary hypertension.
The investigator compared difference between inhaled and intravenous milirinone in patiens
with severe pulmonary hypertension undergoing cardiac surgery
IMPAHCT-FUL: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long
Term Extension (LTE) Trial is a follow up study to establish the long-term safety of AV-101.
The long-term effects of AV-101 on efficacy measures will also be assessed. Subjects who
successfully complete the 24-week placebo-controlled parent trial (AV-101-002) will be
offered the opportunity to continue into this LTE study. Subjects who enroll in the study
will receive one of three active AV-101 doses until such time as the optimal dose has been
selected in the parent study.
Inhaled nitric oxide (iNO) is an effective treatment for pulmonary hypertension (PH) in term
and near-term infants. Preterm infants are at risk for early PH that is associated with high
risk for bronchopulmonary dysplasia or death. In multiple clinical trials, iNO treatment was
not effective for BPD prevention. However, infants were not screened for PH and iNO treatment
was not targeted for PH. iNO treatment for PH in preterm infants is controversial due to lack
of evidence. The study team hypothesizes that early diagnosis of PH (72-96 hours of life) and
iNO treatment will decrease the incidence of death and bronchopulmonary dysplasia and...
This study aims to evaluate the efficacy and safety of inhaled treprostinil in subjects with
sarcoidosis-associated interstitial lung disease and pulmonary hypertension.
Chronic thromboembolic pulmonary hypertension (CTEPH) is characterised by an obstruction of
proximal or more distal pulmonary arteries by residual organized thrombi, combined with a
variable microscopic pulmonary vasculopathy (microvasculopathy). Besides lifelong
anticoagulation, surgical pulmonary endarterectomy is the treatment of choice in subjects
with proximal CTEPH affecting large pulmonary arteries. However, around half of CTEPH
subjects are not operated, mainly because of distal lesions inaccessible to surgery.
International data have reported survival rates of 88, 79, and 70% at 1, 2, and 3 years,
respectively, in subjects...
The primary objective of this study is to determine the impact of two interventions against
insulin resistance on the composite endpoint of 10% improvement in baseline six minute walk
distance or improvement in World Health Organization (WHO) functional class in humans with
pulmonary artery hypertension (PAH).
The purpose of the study is to determine whether patients with pulmonary hypertension (PH)
have dysynchrony, and if so whether it is electrical or mechanical. Once this has been
determined, during a catheterization the investigators will test if pacing the heart improves